logo
  

Hugo Boss FY19 Profit Down, Lifts Dividend; Says Confident Of FY20, Beyond

German luxury fashion brand Hugo Boss AG (HUGSF.PK) reported Thursday that its fiscal 2019 net profit attributable to equity holders of the parent company declined to 205.11 million euros from last year's 236.15 million euros.

Earnings per share were 2.97 euros, down from 3.42 euros last year.

Consolidated net income excluding the impact of IFRS 16 was 212 million euros, down 10 percent.

Operating result or EBIT fell to 344.50 million euros from last year's 346.81 million euros. The company said the weak earnings mainly reflected lower than expected sales growth, increased markdown activity - particularly in North America, and additional investments in retail business.

Group sales increased to 2.88 billion euros from 2.80 billion euros last year.

Further, the company proposed dividend of 2.75 per share for the year, up 2 percent from last year.

Looking ahead, Chief Executive Officer Mark Langer said, "I am very confident that, together, we will achieve our targets for 2020 and beyond."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning. Science and technology firm Danaher Corp. (DHR) announced Thursday that it has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance... Biopharmaceutical company Kite Pharma, a part of Gilead Sciences, Inc. (GILD), and biotechnology company Shoreline Biosciences, Inc. announced Thursday a strategic partnership to develop novel cell therapies across a variety of cancer targets. The partnership follows Kite's investment in Shoreline's...
Follow RTT